{"id":47188,"date":"2022-08-11T14:01:53","date_gmt":"2022-08-11T12:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/"},"modified":"2022-08-11T14:01:53","modified_gmt":"2022-08-11T12:01:53","slug":"privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/","title":{"rendered":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D"},"content":{"rendered":"<div>\n<p>MORRISTOWN, N.J.&#8211;(BUSINESS WIRE)&#8211;Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the company\u2019s proposed generic to Xifaxan\u00ae, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/4\/logo2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg\"><\/a><\/p>\n<p>\n\u201cWe are extremely pleased with the district court\u2019s decision, which brings us one step closer to bringing a more affordable alternative to patients taking Xifaxan for IBS-D,\u201d said Robert Wessman, Chairman of Alvogen.\n<\/p>\n<p>\nMr. Wessman is also the founder and serves as Executive Chairman of Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide.\n<\/p>\n<p>\n<b>About Alvogen<\/b>\n<\/p>\n<p>\nAlvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market. The company has a diverse portfolio and pipeline that includes both branded and generic products across various dosage forms. The Alvogen-family of companies and include Alvogen US (Generics), Almatica (Brands) and Almaject (Injectables).\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<a target=\"_blank\" href=\"&#109;a&#105;l&#116;o&#x3a;E&#x6c;i&#x73;a&#x62;e&#x74;&#46;&#x48;j&#x61;l&#x74;a&#x64;o&#x74;&#116;&#x69;&#114;&#x40;&#97;&#x6c;&#118;&#x6f;&#103;&#x65;&#110;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x45;&#x6c;&#x69;&#x73;&#97;&#98;&#101;&#116;&#46;Hj&#x61;&#x6c;&#x74;&#x61;&#x64;&#111;&#116;&#116;ir&#64;&#x61;&#x6c;&#x76;&#x6f;&#x67;&#101;&#110;&#46;com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MORRISTOWN, N.J.&#8211;(BUSINESS WIRE)&#8211;Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the company\u2019s proposed generic to Xifaxan\u00ae, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults. \u201cWe are extremely pleased with the district court\u2019s &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47188","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MORRISTOWN, N.J.&#8211;(BUSINESS WIRE)&#8211;Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the company\u2019s proposed generic to Xifaxan\u00ae, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults. \u201cWe are extremely pleased with the district court\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-11T12:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D\",\"datePublished\":\"2022-08-11T12:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/\"},\"wordCount\":197,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005336\\\/en\\\/606776\\\/21\\\/logo2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/\",\"name\":\"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005336\\\/en\\\/606776\\\/21\\\/logo2.jpg\",\"datePublished\":\"2022-08-11T12:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005336\\\/en\\\/606776\\\/21\\\/logo2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005336\\\/en\\\/606776\\\/21\\\/logo2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/","og_locale":"en_US","og_type":"article","og_title":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D - Pharma Trend","og_description":"MORRISTOWN, N.J.&#8211;(BUSINESS WIRE)&#8211;Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the company\u2019s proposed generic to Xifaxan\u00ae, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults. \u201cWe are extremely pleased with the district court\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-11T12:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D","datePublished":"2022-08-11T12:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/"},"wordCount":197,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/","url":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/","name":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg","datePublished":"2022-08-11T12:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220811005336\/en\/606776\/21\/logo2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/privately-held-alvogen-announces-favorable-ruling-on-patents-related-to-the-companys-proposed-generic-to-xifaxan-for-ibs-d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47188"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47188\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}